Endometrial preparation for embryo transfer: reproductive outcomes of modified natural cycle versus hormone replacement therapy
Revista Brasileira de Ginecologia e Obstetrícia · 03.11.2026 · 48
DOI: 10.61622/rbgo/2026rbgo66 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Revista Brasileira de Ginecologia e Obstetrícia, erschienen am 03.11.2026. Verfasst von Laura Caetano de Sá und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade Ciências Médicas de Minas Gerais Belo HorizonteMG Brazil Faculdade Ciências Médicas de Minas Gerais, Belo Horizonte, MG, Brazil. Hauptthemen laut MEDLINE: Embryo Transfer, Endometrium, Hormone Replacement Therapy. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
Compare reproductive outcomes between modified natural cycle (mNC) and hormone replacement therapy (HRT) for endometrial preparation in embryo transfer.
Methods
Retrospective cohort study (2020-2024) including 180 cycles that reached embryo transfer at a tertiary center. Primary outcome was biochemical pregnancy (β-hCG positivity), and clinical pregnancy was secondary. Multivariable logistic regression adjusted for baseline imbalances (age, infertility duration, endometriosis, unexplained infertility) and embryonic factors (developmental stage, PGT-A status) was performed. Sensitivity analyses assessed embryonic heterogeneity.
Results
Cohort comprised 68.9% HRT and 31.1% mNC cycles. Baseline differences were observed: mNC had higher rates of endometriosis (41% vs. 25%; p = 0.029), unexplained infertility (30% vs. 9.7%; p < 0.001), and longer infertility duration (median 5 vs. 3 years; p = 0.003), while anovulation was more frequent in HRT (22% vs. 5.4%; p = 0.006). No statistically significant difference in biochemical pregnancy rates was observed between groups (OR 0.87, 95% CI 0.45-1.65; p = 0.682). After adjustment, endometrial preparation protocol was not independently associated with biochemical pregnancy (aOR 1.31; 95% CI 0.51-3.35; p = 0.568). Sensitivity analyses showed consistent results despite blastocyst transfer predominance (75%).
Conclusion
After adjustment for clinical and embryonic confounders, no statistically significant association was observed between endometrial preparation protocol and β-hCG levels or clinical pregnancy among cycles that achieved embryo transfer. Despite retrospective design, limited progesterone data, and exclusion of canceled cycles, mNC may represent a feasible physiological alternative in selected ovulatory patients, although prospective studies are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculdade Ciências Médicas de Minas Gerais Belo HorizonteMG Brazil Faculdade Ciências Médicas de Minas Gerais, Belo Horizonte, MG, Brazil.
- Centro de Reprodução Humana Rede MaterDei de Saúde Belo HorizonteMG Brazil Rede MaterDei de Saúde, Centro de Reprodução Humana, Belo Horizonte, MG, Brazil.
ORCID-Profile: Laura Caetano de Sá, Luma Soares Fagundes, Rivia Mara Lamaita, Ana Márcia de Miranda Cota
Zitieren
APA
de Sá, L. C., Fagundes, L. S., Lamaita, R. M., & Cota, A. M. M. (2026). Endometrial preparation for embryo transfer: reproductive outcomes of modified natural cycle versus hormone replacement therapy. Revista Brasileira de Ginecologia e Obstetrícia, 48. https://doi.org/10.61622/rbgo/2026rbgo66
Vancouver
de Sá LC, Fagundes LS, Lamaita RM, Cota AMM. Endometrial preparation for embryo transfer: reproductive outcomes of modified natural cycle versus hormone replacement therapy. Revista Brasileira de Ginecologia e Obstetrícia. 2026;48. doi:10.61622/rbgo/2026rbgo66
BibTeX
@article{deS2026,
author = {de Sá, Laura Caetano and Fagundes, Luma Soares and Lamaita, Rivia Mara and Cota, Ana Márcia de Miranda},
title = {Endometrial preparation for embryo transfer: reproductive outcomes of modified natural cycle versus hormone replacement therapy},
journal = {Revista Brasileira de Ginecologia e Obstetrícia},
year = {2026},
volume = {48},
doi = {10.61622/rbgo/2026rbgo66}
}
EUVIMED